{"id":"umeclidinium-vilanterol-62-5-25-mcgs","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":{"chemblId":"CHEMBL1187833","moleculeType":"Small molecule","molecularWeight":"428.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Umeclidinium competitively antagonizes M3 muscarinic receptors on airway smooth muscle, reducing acetylcholine-induced bronchoconstriction. Vilanterol activates beta-2 adrenergic receptors, increasing intracellular cAMP and promoting smooth muscle relaxation. The combination provides complementary mechanisms for sustained bronchodilation over 24 hours.","oneSentence":"Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to reduce airway smooth muscle contraction, while vilanterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing dual bronchodilation for sustained airway opening.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:21.941Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance treatment"}]},"trialDetails":[{"nctId":"NCT05342558","phase":"PHASE4","title":"Efficacy and Safety of ICS/LABA vs. LAMA/LABA in Patients With Different COPD Phenotypes.","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2017-09-19","conditions":"COPD","enrollment":133}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anoro"],"phase":"marketed","status":"active","brandName":"Umeclidinium/Vilanterol 62.5/25 mcgs","genericName":"Umeclidinium/Vilanterol 62.5/25 mcgs","companyName":"National Institute of Respiratory Diseases, Mexico","companyId":"national-institute-of-respiratory-diseases-mexico","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Umeclidinium is a long-acting anticholinergic that blocks muscarinic receptors to reduce airway smooth muscle contraction, while vilanterol is a long-acting beta-2 agonist that relaxes airway smooth muscle, together providing dual bronchodilation for sustained airway opening. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}